Durect dives on Posidur rejection
This article was originally published in Scrip
Shares of Durect plummeted 30% in after-hours trading on 12 February after the company revealed it had received a complete response letter (CRL) from the FDA for the drug maker’s post-operative pain relief product Posidur, which uses the firm’s Saber technology to deliver bupivacaine.
You may also be interested in...
Keeping Track: US FDA Closes Out First Half Of 2019 With CRL For Edsivo, But A Burst Of Supplemental Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Sandoz acquires rights to extended-release bupivacaine once held by Nycomed and Hospira in deal paying Durect $20m up front. Video interview: Partners Elasmogen and Feldan collaborate with Amgen.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.